Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Colonic Neoplasms 2Rectal Neoplasms 1Rectal Diseases 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Intestinal Neoplasms 1Intestinal Diseases 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Diseases 1

Interventions

pembrolizumab 25Cisplatin 9Paclitaxel 6Fluorouracil 5Carboplatin 4Saline Solution 3Capecitabine 3Bevacizumab 3Oxaliplatin 2Gemcitabine 2Docetaxel 2Cetuximab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2lenvatinib 1Trastuzumab 1S 1 (combination) 1Irinotecan 1IFL protocol 1Glucose 1Doxorubicin 1Brentuximab Vedotin 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Parkinson Disease 4, Autosomal Dominant Lewy Body × Cetuximab × Clear all
NCT02358031 2025-07-18

MK-3475-048

Merck Sharp & Dohme LLC

Phase 3 Completed
882 enrolled 50 charts 1 FDA
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT02563002 2024-10-03

KEYNOTE-177

Merck Sharp & Dohme LLC

Phase 3 Completed
307 enrolled 16 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡